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Abstract
A quinidine-catalyzed diastereoselective addition of α-angelica lactone to β-halo-α-ketoesters is 
reported. The α-angelica lactone displays unusual regioselectivity in this reaction, acting as a 
nucleophile at the α-position to provide fully substituted glycolic esters with three contiguous 
stereocenters. Subsequent diastereoselective hydrogenation provides an additional stereocenter 
within the lactone.
Graphical Abstract
The construction of contiguous stereogenic polyads is an ongoing challenge in organic 
synthesis. In this context, β-stereogenic α-ketoesters (1) are molecules of interest due to 
their appreciable electrophilicity and their available functional handles for downstream 
transformations.1 Previously, our group has developed a number of methods for their 
synthesis,2 as well as their application in complexity-building transformations encompassing 
a variety of reaction manifolds (i.e., transfer hydrogenation, Henry reaction, acetone aldol, 
benzoin addition, and homoenolate addition; Scheme 1a).3b–3i While these methods have 
provided access to a wide array of fully substituted glycolic acid scaffolds, there are few 
examples of the addition of prochiral nucleophiles.3a,3f, 3g The application of α-angelica 
lactone (2) as a nucleophile presents an interesting opportunity to build more 
stereochemically complex products.
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Unlike previously deployed pro-nucleophiles, α-angelica lactone (2) poses additional 
challenges with respect to (1) reactivity due to the imposition of increased steric bulk; (2) 
regioselectivity (α- vs γ-nucleophilicity of the dienolate); and (3) stereoselectivity (eight 
stereoisomers are possible in the α-addition mode). This class of nucleophile has been 
studied in the stereoselective addition to nitrostyrenes and other prochiral electrophiles using 
cinchona alkaloid-derived thiourea organocatalysts (Scheme 1b).4a Other additions to 
nitrostyrenes,4 aldimines,5 enones,6 enals,7 and vinyl sulfones8 have also been studied. In all 
of these cases, the α-angelica lactone exhibited electrophilic trapping at the γ-carbon. A rare 
example from Boukouvalas achieved α-trapping with α-angelica lactones via in situ 
generation of tin or boron dienolates for addition into aldehydes.9 Herein, we describe initial 
studies toward the creation of complex stereotriads in the form of a quinidine-catalyzed 
diastereoselective aldol addition of α-angelica lactone (2) to β-halo-α-ketoesters (1) 
(Scheme 1c).
Based on the high levels of Felkin-Ahn diastereoselectivity observed with β-halo-α-
ketoesters (1) previously,3b, 3d–3f we selected this substrate class for our investigation. The 
results of aldol reactions using a panel of commercially, and readily-accessible Brønsted 
bases and conditions indicated that quinidine was an optimal catalyst for the 
diastereoselective addition. Quinidine provides a racemic product and to date the maximum 
enantioselectivity observed for the title reaction with any catalyst is 58:42 er (see the 
Supporting Information for full optimization and additional commentary).
Intriguingly, in all cases we studied, capture of the electrophile at the α-position of the 
lactone was the dominant mode of reactivity. We speculate that this divergence may arise 
from the more demanding steric environment imposed by the α-ketoester, as compared with 
those used in previous reports.4–8 Additionally, for the most part, substitution at the β-
position of the α-ketoesters does not affect the intrinsically high diastereoselectivity of the 
reaction. Using β-halo-β-benzyl α-ketoesters, catalyzed addition of α-angelica lactone 
provided the aldol products 3a–3c in modest yields in >20:1 dr (Scheme 2). By comparing 
β-bromo-substituted 3a with β-chloro-substituted 3b, we found that the identity of the 
halogen has no impact on diastereoselectivity. Benzyl-substituted substrates 3d and 3e gave 
>20:1 dr; however, para-chlorophenyl-substituted 3d gave an elevated 73% yield while 
ortho-fluoro-substituted 3c gave 55% yield. Changing the ortho-tolyl group (3e) to a meta-
tolyl group (3f) resulted in a dramatic loss of diastereoselectivity; the reason for this 
decrease in stereoselectivity is unclear. Aliphatic products 3g and 3h were formed 
diastereoselectively in 41% and 48% yield, respectively. While the branched product 3j was 
formed in higher yield relative to other aliphatic substrates, a significantly lower 
diastereoselectivity was observed (4.0:1 dr). We found that the reaction to give 3i was also 
diastereoselective, though low yielding.
The relative stereochemistry afforded by the reaction was determined by an X-ray diffraction 
study performed on the lactone product 3a (Scheme 2).10 In order to rationalize the observed 
stereochemical outcome of the reaction, the Felkin-Anh (or Cornforth) model11 for the 
approach of the nucleophile to the β-halo-α-ketoester can be used, whereby the nucleophile 
approaches anti to the large β-halo substituent (Scheme 3a). In this model, the angelica 
lactone attacks at the Bürgi-Dunitz angle over the smallest β-substituent while the carbonyl 
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is orthogonal to the β-halo group, thereby controlling the relationship between secondary 
halogen-bearing stereocenter and the tertiary alcohol. Governance of the lactone stereocenter 
could arise from the trajectory of the α-angelica lactone that minimizes repulsion between 
the lone pairs on the furanyl oxygen and the carbonyl oxygen (Scheme 3b). We propose that 
hydrogen-bonding with the catalyst facilitates this step and the bifunctional nature of the 
catalyst may help explain its superior performance over Et3N, although stereochemical 
transmission from the chiral catalyst is poor at our current level of optimization.12
Having developed conditions for the diastereoselective generation of 3, we sought to extend 
our stereochemical arrays using downstream reduction of the dihydrofuranone. In the event, 
the resultant stereocenter was provided in >20:1 dr through catalytic hydrogenation (Scheme 
4). A syn relationship between the lactone methine protons was determined through NOESY 
analysis, which is consistent with hydrogenation from the less hindered face of the lactone.
Drawing inspiration from prior work on α-angelica lactones and α-ketoesters, this work 
presents new opportunities for accessing glycolic acid scaffolds. This reaction proceeded 
diastereoselectively for a variety of α-ketoester derivatives. This method represents a 
convenient way to diastereoselectively produce three contiguous stereocenters using a 
commercial organocatalyst. Additionally, this method represents a rare case where α-
angelica lactone behaves as a regioselective α-nucleophile. Future directions for this work 
include investigations into the regioselectivty phenomenon and an expanded study of more 
complex α-angelica lactone nucleophiles.13 Applications of this methodology and 
development of an asymmetric variant are ongoing in our laboratory.
EXPERIMENTAL SECTION
General Comments
Nuclear magnetic resonance spectra (1H NMR, 13C NMR, 19F NMR and 31P NMR) were 
recorded at the following frequencies: 1H NMR at 400 MHz or 600 MHz, 13C NMR at 101 
MHz or 151 MHz, 19F NMR at 376 MHz and 31P NMR at 162 MHz or 243 MHz with 
solvent resonance as the internal standard (1H NMR: CDCl3 at 7.26 ppm and 13C NMR: 
CDCl3 at 77.0 ppm). 1H NMR data are reported as follows: chemical shift, multiplicity (s = 
singlet, br-s = broad singlet, d = doublet, dd = doublet of doublet, t = triplet, td = triplet of 
doublet, m = multiplet), coupling constants (Hz), and integration. Mass spectra were 
obtained using a Finnigan linear trap quadrapol Fourier transform (LTQ-FT) spectrometer. 
TLC visualization was accomplished with UV light, phosphomolybdic acid in ethanol, or 
aqueous ceric ammonium nitrate solution. Yields refer to isolated yields after flash column 
chromatography; some samples contain residual minor diastereomers. Since all results are 
the averages of two trials, the stereoisomer ratios listed in the paper may not exactly match 
those represented in the NMR data below. 2-MeTHF and α-angelica lactone were purchased 
and used as received. β-halo-α-ketoesters were prepared according to literature 
procedures.3b–3e Commercially available quinidine was used as received. Since d.r. and % 
yield values reported in the paper reflect an average of two trials, they may not exactly 
match the isolated yields reported below.
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General procedure for addition of α-angelica lactone to β-halo-α-ketoester
A 1 dram vial was charged sequentially with β-halo-α-ketoester (0.1 mmol, 1.0 equiv), 
followed by 2-MeTHF (1.0 mL), and finally the α-angelica lactone (0.2 mmol, 2.0 equiv). 
The reaction was stirred at room temperature for one min. Quinidine (0.01 mmol, 10 mol %) 
was added in one portion. The reaction was stirred at room temperature for 6 h, then 
concentrated in vacuo. The crude materials thusly obtained were purified using flash column 
chromatography, with a gradient from 95:5 hexanes/EtOAc to 80:20 hexanes/EtOAc.
(±)-Ethyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-3-yl)-4-
phenylbutanoate (3a)—The title compound was prepared according to the general 
procedure; 18.1 mg (47%) was isolated. No minor diastereomer was observed. Light yellow 
solid, mp 114–116 °C; 1H NMR (600 MHz, CDCl3) δ 7.43 (d, J = 7.2 Hz, 2H), 7.36 (t, J = 
7.2 Hz, 2H), 7.30 (t, J = 7.2 Hz, 1H) 5.29 (s, 1H), 5.05 (dd, J = 11.4, 2.4 Hz, 1H), 4.35-4.30 
(m, 1H), 4.26-4.21 (m, 1H), 3.98 (s, 1H), 3.91 (br, 1H), 3.61 (dd, J = 14.4, 2.4 Hz, 1H), 3.03 
(dd, J = 14.4, 11.4 Hz, 1H), 2.03 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 174.0, 171.2, 154.4, 137.9, 129.6, 128.4, 126.9, 100.7, 80.5, 63.4, 58.5, 50.3, 
38.2, 14.1, 13.9; IR (thin film) ν 3433, 2359, 1794, 1747, 1647, 1541, 1456, 1237, 1122, 
944, 777 cm−1; HRMS (ESI): Calcd. For C17H19BrNaO5+ ([M+Na+]): 405.0308, found 
405.0296; TLC (1:5 EtOAc/hexanes): Rf = 0.51.
(±)-Methyl 3-chloro-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-3-yl)-4-
phenylbutanoate (3b)—The title compound was prepared according to the general 
procedure; some impurities remained after repeated silica gel column chromatography; 
NMR yields were calculating using 1,3,5-trimethoxybenzene as an internal standard and 
using the signal of the desired product at δ 5.27 in the crude 1H NMR spectrum. The product 
was obtained in 49% 1H NMR yield. No minor diastereomer was observed. White solid, mp 
70–72 °C; 1H NMR (600 MHz, CDCl3) δ 7.41 (d, J = 7.8 Hz, 2H), 7.36 (t, J = 7.2 Hz, 2H), 
7.29 (t, J = 7.2 Hz, 1H), 5.27 (s, 1H), 4.88 (dd, J = 11.4, 2.4 Hz, 1H), 3.92 (s, 1H), 3.90 (t, J 
= 2.4 Hz, 1H), 3.83 (s, 3H), 3.50 (dd, J = 13.8, 2.4 Hz), 3.89 (dd, J = 13.8, 2.4 Hz), 2.04 (s, 
3H); 13C NMR (151 MHz, CDCl3) δ 174.1, 171.7, 154.7, 137.2, 129.7, 128.4, 127.0, 100.2, 
80.9, 64.5, 53.6, 50.5, 37.7, 14.0; IR (thin film) ν 3461, 1752, 1636, 1455, 1254, 1140, 
1084, 703, 641, 523 cm−1; HRMS (ESI): Calcd. For C16H17ClNaO5+ ([M+Na+]): 347.0675, 
found 347.0648; TLC (1:5 EtOAc/hexanes): Rf = 0.10.
(±)-Isopropyl 3-bromo-4-(2-fluorophenyl)-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)butanoate (3c)—The title compound was prepared according to the 
general procedure; some impurities remained after repeated silica gel column 
chromatography; NMR yields were calculating using 1,3,5-trimethoxybenzene as an internal 
standard and using the signal of the desired product at δ 5.29 in the crude 1H NMR 
spectrum. The product was obtained in 57% 1H NMR yield. No minor diastereomer was 
observed. White solid, mp 92–94 °C, 1H NMR (600 MHz, CDCl3) δ 7.50 (t, J = 7.8 Hz, 
1H), 7.30-7.26 (m, 1H), 7.17-1.15 (m, 1H), 7.09-7.06 (m, 1H), 5.29 (s, 1H), 5.12-5.08 (m, 
2H), 4.00 (s, 1H), 3.88 (s, 1H), 3.46 (d, J = 14.4 Hz, 1H), 3.34 (dd, J = 14.4, 11.4 Hz, 1H), 
2.02 (s, 3H), 1.30 (d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.6 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 173.9, 170.6, 162.1, 154.3, 131.5 (d, J = 4.1 Hz), 128.7 (d, J = 8.0 Hz), 125.0 (d, J 
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= 15.3 Hz), 124.1 (d, J = 3.8 Hz), 115.4 (d, J = 22.2 Hz), 100.7, 79.9, 72.1, 56.5, 50.3, 31.0 
(d, J = 2.1 Hz), 21.4, 21.3,14.1; 19F NMR (376 MHz, CDCl3) δ −117.1; IR (thin film) ν 
3853, 3750, 3649, 3437, 2349, 1653, 1558, 1507, 1457, 716, 578 cm−1; HRMS (ESI): 
Calcd. For C18H20BrFNaO5+ ([M+Na+]): 437.0370, found 437.0356; TLC (1:5 EtOAc/
hexanes): Rf = 0.57.
(±)-Isopropyl 3-bromo-4-(4-chlorophenyl)-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)butanoate (3d)—The title compound was prepared according to the 
general procedure; the crude reaction mixture was purified using flash column 
chromatography; 30.0 mg (70%) was isolated. No minor diastereomer was observed. Yellow 
solid, 117–120 °C, 1H NMR (600 MHz, CDCl3) δ 7.38 (d, J = 8.4 Hz, 2 H), 7.33 (d, J = 8.4 
Hz, 2 H), 5.28 (s, 1H), 5.09 (m, 1H), 4.97 (s, 1H), 5.00 (dd, J = 11.4, 2.4 Hz, 1H), 3.98 (s, 
1H), 3.86 (t, J = 2.4 Hz, 1H), 3.55 (dd, J = 14.4, 1.8 Hz), 3.02 (dd, J = 14.4, 2.4 Hz, 1H), 
2.03 (s, 3H), 1.27 (dd, 12.6, 6.6 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 174.1, 170.6, 
154.4, 136.4, 132.8, 131.1, 128.5, 100.7, 80.0, 72.1, 58.2, 50.2, 37.6, 21.4 (d, J = 8.9 Hz), 
14.1; IR (thin film) ν 3421, 2359, 1794, 1741, 1635, 1495, 1102, 944, 813, 536 cm−1; 
HRMS (ESI): Calcd. For C18H20BrClNaO5+ ([M+Na+]): 453.0075, found 453.0068; TLC 
(1:5 EtOAc/hexanes): Rf = 0.30.
(±)-Tert-butyl 3-chloro-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-3-yl)-3-(o-
tolyl)propanoate (3e)—The title compound was prepared according to the general 
procedure; the crude reaction mixture was purified using flash column chromatography; 15.8 
mg (43%) was isolated. No minor diastereomer was observed. White solid, mp 143–
144 °C, 1H NMR (600 MHz, CDCl3) δ 7.86 (br, 1H), 7.21-7.20 (m, 2H), 7.14 (m, 1H), 6.40 
(s, 1H), 5.30 (s, 1H), 4.14 (s, 1H), 4.12 (t, J = 3.6 Hz, 1H), 2.49 (s, 3H), 2.02 (s, 3H), 1.16 (s, 
9H); 13C NMR (151 MHz, CDCl3) δ 174.4, 169.5, 153.8, 136.1, 135.5, 103.2, 129.0, 128.9, 
126.7, 100.4, 85.7, 80.3, 55.7, 51.3, 27.2, 19.6, 14.1; IR (thin film) ν 3853, 3839, 3734, 
3649, 3446, 2390, 1653, 1558, 1540, 1507, 578, 508 cm−1; HRMS (ESI): Calcd. For 
C19H23ClNaO5+ ([M+Na+]): 389.1126, found 389.1114; TLC (1:5 EtOAc/hexanes): Rf = 
0.57.
(±)-Tert-butyl 3-chloro-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-3-yl)-3-
(m-tolyl)propanoate (3f)—The title compound was prepared according to the general 
procedure; the crude reaction mixture was purified using flash column chromatography; 16.0 
mg (44%) was isolated. The diastereoselectivity was determined by comparing the signals at 
δ 5.86 (major) and δ 5.81 (minor). Trace amounts of both diastereomers of the γ–addition 
product were also observed in the crude 1H NMR spectrum, and were identified after 
separation by column chromatography. White solid, mp 133–135 °C; 1H NMR (600 MHz, 
CDCl3) δ 7.32 (d, J = 7.8 Hz, 1H), 7.29 (s, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.14 (d, J = J = 7.8 
Hz, 1H), 5.87 (s, 1H), 5.28 (s, 1H), 4.16 (t, J = 2.4 Hz, 1H), 3.82 (s, 1H), 2.35 (s, 3H), 2.02 
(s, 3H), 1.32 (s, 9H); 13C NMR (151 MHz, CDCl3) δ 174.2, 169.4, 153.6, 137.7, 135.9, 
129.9, 129.7, 128.1, 126.2, 100.5, 85.8, 80.2, 62.1, 50.9, 27.5, 21.4, 14.1; IR (thin film) ν 
3853, 3837, 3801, 3734, 3627, 2360, 2341, 1683, 1539, 1244, 791, 668 cm−1; HRMS (ESI): 
Calcd. For C19H23ClNaO5+ ([M+Na+]): 389.1126, found 389.1114; TLC (1:5 EtOAc/
hexanes): Rf = 0.62.
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(±)-Isopropyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-3-
yl)butanoate (3g)—The title compound was prepared according to the general procedure; 
the crude reaction mixture was purified using flash column chromatography; 14.0 mg (44%) 
was isolated. No minor diastereomer was observed. White solid, mp 84–85 °C, 1H NMR 
(600 MHz, CDCl3) δ 5.25 (s, 1H), 5.10 (m, 1H), 4.98 (q, 1H), 3.81 (s, 1H), 3.64 (t, 1H), 
2.00 (s, 3H), 1.87 (d, J = 6.6 Hz, 1H), 1.28 (dd, J = 33.6, 6.0 Hz, 6H); 13C NMR (151 MHz, 
CDCl3) δ 173.9, 170.9, 154.1, 100.7, 79.9, 71.8, 50.7, 50.1, 21.5, 21.3,19.7, 14.0; IR (thin 
film) ν 3446, 2393, 1740, 1653, 1287, 1102, 782, 579, 519, 503 cm−1; HRMS (ESI): Calcd. 
For C12H17BrNaO5+ ([M+Na+]): 343.0152, found 343.0146; TLC (1:5 EtOAc/hexanes): Rf 
= 0.39.
(±)-Isopropyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-dihydrofuran-3-
yl)hex-5-enoate (3h)—The title compound was prepared according to the general 
procedure; the crude reaction mixture was purified using flash column chromatography; 18.0 
mg (54%) was isolated. No minor diastereomer was observed. Clear oil, 1H NMR (600 
MHz, CDCl3) δ 5.60–5.93 (m, 1H), 5.27-5.21 (m, 3H), 5.10 (quintet, J = 6.0 Hz, 1H), 4.83 
(dd, J = 10.8, 3.0 Hz, 1H), 3.89 (s, 1H), 3.79 (br, 1H), 2.95-2.91 (m, 1H), 2.69-2.64 (m, 1H), 
2.00 (s, 3H), 1.31 (d, J = 6.6 Hz, 3H), 1.26 (d, J = 6.6 Hz, 3H); 13C NMR (151 MHz, 
CDCl3) δ 173.9, 170.6, 154.2, 134.6, 118.3, 100.6, 79.9, 72.0, 56.3, 50.2, 36.5, 21.5, 21.3, 
14.1; IR (thin film) ν 3448, 1797, 1739, 1646, 1249, 1182, 1102, 945, 607, 505 cm−1; 
HRMS (ESI): Calcd. For C14H19BrNaO5+ ([M+Na+]): 369.0308, found 369.0297; TLC 
(1:5 EtOAc/hexanes): Rf = 0.35.
(±)-Isopropyl 5-(benzyloxy)-3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)pentanoate (3i)—The title compound was prepared according to the 
general procedure; the crude reaction mixture was purified using flash column 
chromatography; 13.3 mg (30%) was isolated. No minor diastereomer was observed. Clear 
oil, 1H NMR (600 MHz, CDCl3) δ 7.41-7.28 (m, 5H), 5.25 (s, 1H), 5.14-5.09 (m, 1H), 4.98 
(dd, J = 11.1, 2.4 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 4.57 (d, J = 11.1 Hz, 1H), 4.00 (s, 1H), 
3.80-3.79 (m, 2H), 2.48-2.43 (m, 1H), 2.19-2.13 (m, 1H), 2.00 (s, 3H), 1.39-1.35 (m, 1H), 
1.32 (d, J = 6.0 Hz, 3H), 1.27 (d, J = 6.0 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.8, 
170.7, 154.2, 138.3, 128.4, 127.7, 127.6, 100.6, 80.0, 72.9, 71.9, 68.0, 54.1, 50.4, 32.0, 21.5, 
21.4, 14.1; IR (thin film) ν 3464, 2389, 1738, 1640, 1102, 788, 699, 607, 526−1; HRMS 
(ESI): Calcd. For C20H25BrNaO6+ ([M+Na+]): 463.0727, found 463.0708; TLC (1:5 
EtOAc/hexanes): Rf = 0.27.
(±)-Isopropyl 3-bromo-2-hydroxy-4-methyl-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)pentanoate (3j)—The title compound was prepared according to the 
general procedure; the crude reaction mixture was purified using flash column 
chromatography; 20.0 mg (57%) was isolated. The diastereoselectivity was determined by 
comparing the signals at δ 4.82 (major) and δ 5.04 (minor). White solid, mp 150–
152 °C, 1H NMR (600 MHz, CDCl3) δ 5.25 (s, 1H), 5.08 (m, 1H), 4.82 (d, J = 1.8 Hz, 1H), 
3.87 (s, 1H), 3.81 (t, J = 2.4 Hz, 1H), 2.37 (m, 1H), 2.0 (s, 3H), 1.28 (dd, J = 37.2, 6.0 Hz, 
6H), 1.15 (dd, J = 26.4, 6.6 Hz, 6H); 13C NMR (151 MHz, CDCl3) δ 173.9, 171.2,154.0, 
100.9, 80.9, 71.9, 65.3, 50.7, 29.8, 23.2, 21.4, 21.3, 18.0, 14.0; IR (thin film) ν 3459, 2968, 
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1796, 1736, 1647, 1388, 1271, 1104, 942, 780 cm−1; HRMS (ESI): Calcd. For 
C14H21BrNaO5+ ([M+Na+]): 371.0465, found 371.0453; TLC (1:5 EtOAc/hexanes): Rf = 
0.52.
(±)-Ethyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxotetrahydrofuran-3-yl)-4-
phenylbutanoate (4a)—A 1 dram vial was charged with 10% Pd/C (40 w/w %) and 
flushed with nitrogen. A solution of ethyl 3-bromo-2-hydroxy-2-(5-methyl-2-oxo-2,3-
dihydrofuran-3-yl)-4-phenylbutanoate (3a) (0.1 mmol, 1.0 equiv) dissolved in EtOAc (1 mL) 
was added. The solution was sparged with H2 for 5 min. The reaction was then allowed to 
stir for 72 h in a high-pressure reactor under 120 psi H2. The reaction mixture then was 
filtered through a celite plug, rinsing with ethyl acetate, and concentrated in vacuo. The 
crude materials thusly obtained were purified using flash column chromatography, with a 
gradient from 95:5 hexanes/EtOAc to 80:20 hexanes/EtOAc to yield 25.0mg (64%) desired 
product in >20:1 dr. Clear oil, 1H NMR (600 MHz, CDCl3) δ 7.36-7.28 (m, 5H), 4.59-4.55 
(m, 1H), 4.46-4.42 (m, 3H), 4.04 (br, 1H), 3.77 (dd, J = 12.0, 9.0 Hz, 1H), 3.55 (d, J = 14.4 
Hz, 1H), 2.70 (dd, J = 14.1, 12.0 Hz, 1H), 2.63-2.58 (m, 1H), 1.88-1.83 (m, 1H), 1.46 (d, J = 
6.0 Hz, 3H), 1.41 (t, J = 7.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 174.5, 171.9, 138.0, 
129.3, 128.4, 127.0, 78.4, 75.0, 63.4, 58.0, 48.1, 38.6, 32.2, 20.9, 14.2; IR (thin film) ν 
3776, 3453, 2391, 2349, 1767, 1642, 1260, 749, 543 cm−1; HRMS (ESI): Calcd. For 
C17H21BrNaO5+ ([M+Na+]): 407.0465, found 407.0454; TLC (1:5 EtOAc/hexanes): Rf = 
0.24.
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Scheme 1. 
Proposed addition of α-angelica lactone to stereogenic α-ketoester
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Scheme 2. Scope of the reactiona
aReaction was conducted on 0.1 mmol scale, using 2.0 equiv of α-angelica lactone. bYield 
was determined by 1H NMR using 1,3,5-trimethoxybenzene as an internal standard.
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Scheme 3. 
Stereochemical model for addition of angelica lactone to β-halo α-ketoester
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Scheme 4. 
Hydrogenation of addition producta
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